Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Pfizer, Hospira acquisition gets European Union approval

The deal was initially a concern for the agency over fear of discontinued drugs, affordability and development of new medications.

European Union regulators approved Pfizer's $16 billion deal to buy Hospira after they conceded to put a plan in place that would protect against price increases, protect research and development, as well as make sure certain drugs were not discontinued, according to the Wall Street Journal.

"This is not just about keeping prices low for patients and health care services,”  Margrethe Vestager, the EU's antitrust chief said in a statement, according to the news organization. “We have also made sure that the merger of Pfizer/Hospira doesn't stand in the way of the research and development of medication that could have huge benefits for society.”

Specifically, regulators were worried about a copycat version of Infliximab, a drug used to treat autoimmune diseases. Their concern was delays or discontinuation of production.

Although the deal was announced in February, they still needed proper regulatory approval.

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
Researched List: Blister Machines for Life Sciences
Need a blister machine for life sciences packaging? Our curated list features companies serving pharmaceutical, medical device, nutraceutical, and cosmetic industries. Download to access company names, locations, machine specifications, descriptions, and more.
Download Now
Researched List: Blister Machines for Life Sciences